Jonathan S Serody
Overview
Explore the profile of Jonathan S Serody including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
8949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hyun H, Sun B, Yazdimamaghani M, Wielgus A, Wang Y, Montgomery S, et al.
J Clin Invest
. 2025 Mar;
PMID: 40067370
Biological targeting is crucial for effective cancer treatment with reduced toxicity but is limited by the availability of tumor surface markers. To overcome this, we developed a nanoparticle-based, Tumor-specific suRfACE...
2.
Reiss K, Angelos M, Dees E, Yuan Y, Ueno N, Pohlmann P, et al.
Nat Med
. 2025 Feb;
PMID: 39920391
Chimeric antigen receptor (CAR) macrophages (CAR-Ms) mediate antitumor immunity via phagocytosis, cytokine release, activation of the tumor microenvironment and antigen presentation. We report results from a non-prespecified interim analysis of...
3.
Andermann T, Brown D, Holowka T, Bartelt L, Serody J, Armistead P, et al.
Open Forum Infect Dis
. 2025 Jan;
12(1):ofae760.
PMID: 39817037
Background: Antimicrobial resistance is a global public health emergency. Patients undergoing hematopoietic stem cell transplantation (HCT) are at increased risk for severe infections with multidrug-resistant (MDR) organisms, although more data...
4.
Yazdimamaghani M, Kolupaev O, Lim C, Hwang D, Laurie S, Perou C, et al.
Biomaterials
. 2024 Sep;
314:122831.
PMID: 39278788
No abstract available.
5.
Yazdimamaghani M, Kolupaev O, Lim C, Hwang D, Laurie S, Perou C, et al.
Biomaterials
. 2024 Aug;
312:122750.
PMID: 39126779
Infiltration of immunosuppressive cells into the breast tumor microenvironment (TME) is associated with suppressed effector T cell (Teff) responses, accelerated tumor growth, and poor clinical outcomes. Previous studies from our...
6.
Cao F, Xiu Y, Mohnasky M, Serody J, Armistead P, Dotti G, et al.
medRxiv
. 2024 Jul;
PMID: 39040188
Key Points: 1) The incidence of infections within the first year after CD30.CAR T-cell therapy was equivalent to that following CD19.CAR T-cell therapy2) Viral infections were more common after CD30.CAR...
7.
Laurie S, Foster 2nd J, Bruce D, Bommiasamy H, Kolupaev O, Yazdimamaghani M, et al.
Nat Commun
. 2024 Jul;
15(1):6000.
PMID: 39019846
Type II innate lymphoid cells (ILC2s) maintain homeostasis and barrier integrity in mucosal tissues. In both mice and humans, ILC2s poorly reconstitute after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Determining...
8.
Beckabir W, Zhou M, Lee J, Vensko S, Woodcock M, Wang H, et al.
Nat Commun
. 2024 May;
15(1):4448.
PMID: 38789460
Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC). Immune checkpoint inhibition (ICI) alone, and ICI in combination with chemotherapy, have demonstrated promising pathologic response (<pT2) in...
9.
Yazdimamaghani M, Kolupaev O, Lim C, Hwang D, Laurie S, Perou C, et al.
bioRxiv
. 2024 Apr;
PMID: 38559220
Infiltration of immunosuppressive cells into the breast tumor microenvironment (TME) is associated with suppressed effector T cell (Teff) responses, accelerated tumor growth, and poor clinical outcomes. Previous studies from our...
10.
Grover N, Hucks G, Riches M, Ivanova A, Moore D, Shea T, et al.
Lancet Haematol
. 2024 Mar;
11(5):e358-e367.
PMID: 38555923
Background: Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T...